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Islet cell transplantation offers a potential cure for type 1 diabetes, but it is challenged by insufficient donor tissue and side effects of
current immunosuppressive drugs. Therefore, alternative sources of insulin-producing cells and isletfriendly immunosuppression
are required to increase the efficiency and safety of this procedure. Beta cells can be transdifferentiated from precursors or
another heterologous (non-beta-cell) source. Recent advances in beta cell regeneration from somatic cells such as fibroblasts could
circumvent the usage of immunosuppressive drugs. Therefore, generation of patient-specific beta cells provides the potential of an
evolutionary treatment for patients with diabetes.
1. Introduction
Type 1 diabetes is one of the most common chronic
diseases in children and adolescents caused by autoimmune
destruction of insulin-producing beta cells of islets of
Langerhans. Thus patients depend on insulin injection all
their life. The majority of young patients depend on life-long
treatment with insulin injections to control hyperglycemia.
However, an exogenous supply of insulin often leads to
severe hypoglycemia-related complications. Hence, insulin
therapy saves life but is not a cure. On the other hand,
beta-cell replacement therapy by transplantation may offer
a cure because transplantation of functional beta cells can
reestablish glucose-responsive insulin secretion and provide
optimal control to prevent hypoglycemia when insulin is
secreted [1–9]. Whole-pancreas transplantation can restore
endogenous insulin production, but it has rarely been carried
out in children with diabetes due to the risk of perioperative
morbidity related to the damage by digestive enzymes from
the exocrine pancreas during the surgical procedure. In con-
trast, islet-cell transplantation provides insulin-producing
beta cells in a relatively noninvasive manner. It becomes a
more feasible option for young recipients. In fact, much
progress has been made in islet-cell transplantation following
the success of the Edmonton protocol that emphasizes both
a sufficient amount of donor islets and steroid-free immuno-
suppressive regimens [3, 4, 8, 9]. However, the requirement
of 2 to 4 donors to reverse diabetes results in a considerable
lack of transplantable islets. The destruction of transplanted
islets by the cytotoxicity of immunosuppressive drugs further
worsens this shortage [7]. In this regard, use of an alternative
source of beta cells is a key to bridge the gap between cell
supply and demand. Therefore, a major goal of diabetes
therapy is to promote the formation of new beta cells. In
consideration of elimination of immunosuppressants, autol-
ogous cells may offer a safer alternative. Ideally, a patient-
specific approach can enhance the success and safety of islet
transplantation.
The pancreas is fundamental to the regulation of nutri-
tional homeostasis. The pancreas is composed of exocrine
and endocrine compartments. The former consists of aci-
nar and ductal cells that produce and transport digestive
enzymes into the duodenum, and the latter of the islets
of Langerhans that make hormones for adaptive glucose
metabolism. Each islet can secret five hormones (glucagon,
insulin, somatostatin, ghrelin, and pancreatic polypeptide),














Figure 1: Generation of pancreatic beta cells. New beta cells can be generated by manipulation of different cell sources, such as from other
endocrine, exocrine, and nonpancreatic cells, induced pluripotent stem cells, embryonic stem cells, and somatic cells.
which are produced by alpha, beta, delta, epsilon, and PP
cells, respectively [10].
There is a great interest in developing novel sources of
transplantable beta cells for replacement therapy. Adult beta
cells possess a limited capacity to replicate under normal
physiologic conditions. However, beta-cell mass expands
during times of metabolic changes such as during pregnancy
and obesity [11, 12]. Beta cells can also be regenerated after
the destruction of existing beta cells, such as by chemical
treatment with streptozotocin or the partial removal of
pancreas by a surgical procedure [13, 14]. In theory, new
beta cells could arise through differentiation of progenitors
or other nonbeta cells (Figure 1). Embryonic stem cells
have the ability to differentiate into any cell type. For this
reason, they are considered as an ideal starting material [15–
18]. Some nonpancreatic cells, including hepatic cells, can
also differentiate into insulin-positive cells [19, 20]. Non-
endocrine pancreatic cells, such as ductal and acinar cells,
may retain a degree of plasticity to differentiate into other
cell types, including beta cells [21–24]. Beta cells can also be
transdifferentiated from other endocrine cells, such as alpha
cells [25–27].
Recent advances in stem cell biology have established
the feasibility of converting one cell type into another [28–
31]. This breakthrough directs autologous cell therapy that
drives the transdifferentiation of readily available cells, such
as fibroblasts, into therapeutically desirable cells, such as
blood, neuron, cardiomyocyte, and islet-like cells. Significant
applications of such patient-specific therapy include the
engineering of new beta cells from patients’ own cells, and
the elimination of the life-long usage of immunosuppres-
sants, bioincompatibility, and disease transmission coupled
with donor cells. Transcription factors for pancreatic stem
cell development and the differentiation of beta cell play a
critical role in this process.
2. Transcription Factors Determine the
Development of Beta Cells
Transcription factors have been recognized as the key
mediators of cellular identity. Cell-specific gene expression
is controlled at the transcriptional level and in large part
by the interface among multiple transcription factors inter-
acting with the promoter and/or enhancer regions of target
genes. Many attempts have been made towards generating
functional beta cells. The importance of transcription factors
in pancreatic development has been well characterized in
knockout and transgenic mice using the reverse genetic
approach of loss- and gain-of-function of the target genes
(Figure 2, [32–35]).
The pancreas develops from dorsal and ventral budding
of the foregut boundary beginning around at embryonic day
9 (E9) in mice and at around 3 weeks postfertilization in




































Figure 2: Development of pancreatic beta cells and the associated transcription factors that required for lineage specificity in various steps.
Alpha-, beta-, delta-, and pp-cells secrete glucagon, insulin, somatostatin, and pancreatic polypeptide, respectively.
humans [36]. Both loss- and gain-of-function approaches
have confirmed the key role of pancreatic and duodenal
homeobox 1 (Pdx1), also known as insulin promoter factor
1, in pancreas development. Genetics lineage tracing has
determined the multipotent ability of Pdx1-positive cells,
which give rise to all pancreatic cell types [18, 19]. The
expression of Pdx1 in abundantly restricted in beta cells in
adulthood, although it exhibits a broad and dynamic expres-
sion pattern during the developmental stage. The absolute
requirement of Pdx1 in normal pancreatic development was
well established in Pdx1-deficient mice, which completely
lack a pancreas [32, 33]. Furthermore, this the phenotype of
pancreatic aplasia was also observed in either heterozygous
or homozygous Pdx1 mutations [34]. In humans, mutations
in one allele of the Pdx1 gene are associated with adult-onset
diabetes (a form of monogenic diabetes), while homozygous
mutations in Pdx1 result in pancreatic aplasia [34]. The
function of Pdx1 is also demonstrated in studies of gain-
of-function. Several studies have shown that nonbeta cells
could be transdifferentiated into functional beta cells by
overexpression of Pdx1 [25]. Ectopic overexpression of Pdx1
activates pancreatic genes in nonpancreatic cells, and these
Pdx1-expressing liver cells can ameliorate streptozotocin-
induced diabetes [20]. Therefore, this gene plays an impor-
tant role in the initial stages of pancreatic development, and
it has a great potential as a manipulative target for generating
insulin-producing beta cells.
Endocrine versus nonendocrine cell fates appear to be
governed by the differential synthesis of the basic helix-
loop-helix (bHLH) transcription factors, Ngn3 (neurogenin
3), Hes1 (hairy and enhancer of split 1), and NeuroD1
(neurogenic differentiation 1). Ngn3 is characterized as an
endocrine cell-specifying factor, the expression of which is
essential for all endocrine-cell development [37, 38]. Lineage
analysis of Ngn3-derived cells reveals that all endocrine cell
types transiently express Ngn3 during a narrow window
in the developing mouse embryo. Ngn3 is detectable at
E13.5, peaks at E15.5, and disappears entirely thereafter. No
Ngn3-positive cells are found at birth or in adult pancreas,
suggesting a role in a particular stage of the pancreas
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development. In fact, Ngn3-deficient mice proceed along
nonendocrine cell fates, confirming its central role as an
endocrine progenitor [37, 38]. One key target gene of Ngn3
is NeuroD1, which appears to lie immediately downstream
of Ngn3, based on the fact that no NeuroD1 can be found
in Ngn3-deficient mice and that expression of Pdx1 is
unaffected in NeuroD1 knockout mice. The expression of
NeuroD1 can be found in pancreatic endocrine cells and
other nonpancreatic tissues, such as the intestine and the
brain. The function of NeuroD1 is to activate the insulin
gene and drive further differentiation into functional islet
cells. In fact, the development of islet cells is arrested at a
premature stage in NeuroD1-deficient mice, demonstrating
a critical role in early islet formation [39].
The transition from endocrine to individual cell types
occurs in two distinct steps. The primary transition features
clusters of first-wave glucagon-positive and insulin-negative
cells at E9.5. Insulin-positive cells appear during the sec-
ondary transition period around E13.5 to E15.5. These cells
proliferate and form islet cells soon after birth. The transition
from the first to the second stage is not random, but
rather each one of the specific endocrine lineages is directed
by additional transcription factors. The paired homeobox
transcription factors 4 and 6 (Pax4 and Pax6) provide an
additional level of specificity for pancreas. Mice deficient for
Pax4 display absence of beta and delta cells, suggesting its role
in directing the fate of those cells [40]. Pax6 knockout mice
fail to develop glucagon-secreting cells, signifying its role in
the commitment towards alpha-cell lineage [41].
Arx expression is restricted to islet at mature stage
although it is expressed in the pancreas during development.
Arx appears to be downstream of Ngn3 based on the fact that
it is not expressed in Ngn3-deficient pancreata [42]. Arx-
deficient mice die prematurely due to severe hypoglycemia,
indicating a possible role in alpha cell development. In
fact, a complete loss of alpha cells in the pancreas from
Arx knockout mice was observed, confirming that Arx is
necessary for alpha cell development [42]. Overexpression
of Arx in either Pdx1-positive progenitor cells or insulin-
producing cells leads to an increase or conversion in alpha
cells, suggesting that Arx is sufficient to turn beta cells
towards alpha cell identity [43].
Brain4 (Brn4), a POU domain transcription factor, is
only expressed in glucagon positive cells of the adult rat
pancreas, suggesting a potential role in alpha cell lineage
[44, 45]. Ectopic expression of Brn4 in beta cells leads to
the conversion of glucagon-positive cells in both the mantle
and the centre of the islet, which led to coexpress insulin
and glucagon, suggesting that Brn4 might play a role in early
development of glucagon-expressing cells [44]. However,
Brn4 is not essential for alpha fate as Brn4-null mutant
mice show no significant impact on glucagon or insulin gene
expression, biosynthesis, or secretion [45].
The insulin promoter region contains binding sites
for both the NK homeobox factors Nkx2.2 and Nkx6.1,
indicating that these factors may direct differentiation of
insulin-producing beta cells. Nkx6.1 exhibits distinct expres-
sion patterns during early and late embryonic stages. It is
expressed exclusively in the beta cells by the end of gestation,
although it can be stained broadly in the pancreas at E10.5.
Mice deficient in Nkx6.1 have no insulin-positive beta cells
but are normal for other islet cell types, demonstrating its
central role in final differentiation of beta cells [46]. Unlike
Nkx6.1, Nkx2.2 can be detected in alpha and PP cells in
addition to beta cells. Mice deficient for Nkx2.2 display a
complete beta-cell loss and reduced numbers of alpha and
PP cells, suggesting its preferential roles in these three cell
lineages during pancreatic development [47].
Although certain transcription factors hold specificity,
other transcription factors may be required in multiple stages
of beta-cell development, and several transcription factors
interact with each other to maintain normal pancreatic
function. Leucine zipper transcription factors Mafa and
Mafb are preferentially expressed within the beta and alpha
cells of the adult pancreas, respectively [48, 49]. The tran-
scription of insulin and glucagon is regulated by Mafa and
Mafb, respectively. Mice deficient in Mafb exhibit reduced
numbers of both insulin- and glucagon-positive cells during
pancreatic development, suggesting its essential role in both
alpha- and beta-cell differentiation [49]. Mice deficient in
Mafa display normal beta-cell development early on, but
they develop beta-cell dysfunction and diabetes as adults
[48]. This normal phenotype of early beta-cell development
in Mafa knockout animals is thought to be due to the
compensation from Mafb. Mafb is also found to be expressed
in nearly 90% of insulin-producing cells in addition to alpha
cells, although this expression ability of Mafb-insulin double
positive cells relies on Nkx6.1 expression, in large part due
to the lack of insulin-positive cells when Nkx6.1 is knocked
down [46, 49]. Forced expression of multiple transcription
factors can induce the capacity of differentiation from cell
type to another. Experimental data show that combination of
the three transcription factors Ngn3, Pdx1, and Mafa directs
the reprogramming of differentiated pancreatic exocrine cells
from adult mice into islet-like cells [22].
The knowledge on transcription factors is believed to be
essential for tailoring the transplantable beta cells to func-
tion optimally. First, multiple transcription factors instead
of one direct specific cell lineages so that combinatorial
interactions obviously are essential for the final pattern of
certain cell types. Second, although transcription factors
direct the formation of new beta cells, other factors, such
as growth factors and transcriptional coactivators are, also
needed.
3. Endocrine Progenitor Cells
Although the turnover of adult human beta cells is rare,
reprogramming may be easier if the starting cell type shares
a common developmental history with the desired cell type.
The transcription factor Ngn3 directs the formation of the
endocrine alpha and beta cells [37, 38]. The development of
alpha cells is earlier than that of beta cells. After the endocrine
cell types start developing, the glucagons-positive alpha cells
become the first to be detectable as early as E9.5. This is
followed by the existence of insulin-producing cells, which
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coexpress glucagon. The fully differentiated beta and alpha
cells can be found by E14 [37, 38].
Once fully functional endocrine cells are developed, cell-
cell contacts between alpha and beta cells are the greatest
among others [25, 26, 37]. For example, the contact rate of
alpha and beta cells is much higher than that of alpha-alpha
or beta-beta cell contact. This enormous contact between
beta and alpha cells suggests a close relationship between
these two cell types. In fact, experimental data reveal that
alpha cells can serve as a novel source of beta-cell progen-
itors. Alpha-to-beta cell conversion has been demonstrated
independently using different damage models [26, 27].
Detailed studies are needed to clarify the factors mediating
the conversion process and the possibility of application to
humans.
4. Nonendocrine Progenitor Cells
During development, endocrine cells, such as beta cells, and
exocrine cells, such as ductal and acinar cells, derive from
the same progenitor cells. Adult ductal epithelium has been
considered as the most likely source of beta-cell progenitors.
This consideration is based on the fact that embryonic
insulin-producing cells arise from pancreatic ductal epithe-
lial progenitor cells using morphological staining of beta
cells, which are frequently existing in the duct or nearby and
also in lineage-tracing studies [24, 50]. It has been found that
significant beta-cell neogenesis results from ductal ligation,
but this could not be confirmed in other studies [24, 50].
Therefore, the plasticity of ductal cells as progenitors to
differentiate into beta cells is still under debate.
Similarly, mouse pancreatic acinar cells can be converted
into beta cells using three transcription factors [22]. The
newly generating insulin-positive cells were detected by irre-
versible genetic lineage-tracing techniques and are confirmed
to derive from acinar cells [22, 23]. Therefore, both ductal
and acinar cells in the exocrine compartment have the
potential to be an alternative source for differentiation into
beta cells.
5. Nonpancreatic Cells
The liver and the pancreas share a common progenitor cell
during embryonic development [19, 20]. Therefore, the liver
has been examined as an alternative source for generating
beta cells [19, 20]. In fact, insulin-positive cells have been
produced either in a non-lineage-restricted manner in the
presence of high glucose and nicotinamide, or by tissue-
specific expression of Pdx1 by adenoviral transfection and
with addition of special soluble factors for beta-cell growth
[19, 20].
6. Inducible Pluripotent Stem Cells (iPSs)
Stem cells possess great plasticity to differentiate into any cell
type. However, adult multipotent stem cells are extremely
rare and difficult to isolate. Induced pluripotent stem cells
(iPSs) are similar to embryonic stem cells and are inducible
ex vivo. iPSs can be reprogrammed by defined factors from
somatic cells [51–54]. Under special conditions, such as
the addition of growth factors and multiple transcription
factors, iPSs can differentiate into some desired cell types.
The significance of this patient-specific conversion would be
the avoidance of the risk of immunological rejection.
The desired cell types can be reprogrammed from abun-
dant somatic cells by two major pathways, either directly
or indirectly. In the former, beta cells are derived directly
from somatic cells, such as fibroblasts [28–31]. They can
also be generated through an iPS stage or as the so-called
indirect pathway. Novel findings show that islet-like insulin-
producing cells can be converted from iPSs, demonstrating
the possibility of using patient-specific iPSs as a source of
transplantable beta cells for cell-replacement therapies in
diabetes. The fact that iPSs can be generated by defined
factors using somatic cells makes this strategy possible.
Directed reprogramming refers to as direct conversion of
beta cells from somatic cells without a multipotent or
pluripotent intermediate, mostly directed by a combination
of the addition of special growth factors and overexpression
of key transcription factors. Fibroblasts can be repro-
grammed directly into insulin-producing cells, neurons,
cardiomyocytes, and blood-cell progenitors, demonstrating
the possibility of converting from one defined cell type to
another. Both direct and indirect pathways for regenerating
new beta cells have a great impact on patient-specific therapy
in the future [28–31].
7. Conclusion
The success of generating islet-like insulin-producing cell
is largely achieved by using our knowledge of the major
steps in the differentiation of beta cells during embryonic
development of the pancreas. The multiple transcription
factors have been applied to coerce available cells to differ-
entiate into desired types in a unique delineation pathway,
including across lineages, such as from fibroblasts into iPSs,
or from one fully functional lineage to another, such as from
fibroblasts into insulin-positive cells. However, major safety
issues are still a concern. For example, lentiviruses that are
used in the expression of defined factors are unlikely to gain
acceptance for transplantation into human patients due to
their ability to integrate into the host genome. One of the
goals of clinical trials is to balance both safety and efficiency.
In terms of safety, some alternate, safer methods, such
as the use of nonintegrable viruses, transferring plasmids,
soluble proteins of reprogramming mediators, and repeated
transfection of mRNA encoding the defined factors, are
being tested as an alternative substitute for lentiviruses [52–
54]. Although the experiments have been carried out as
proof of principle, low efficiency is still an issue for large-
scale production in therapeutic applications. Despite the
promising progress in the search for alternative sources of
insulin-producing beta cells, functionality of new generating
cells that replace the same type in vivo should be measured
considerably. These new transplantable beta cells must
mimic extremely closely the function of the normal beta cells
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if long-term normoglycemia is hoped to be achieved. This
is particularly challenging to the production of true insulin-
producing cells, due to the enormous complexity of the beta
cell. Therefore, it is of great importance to understand in
detail the mechanisms that control the origin and fate of beta
cells if we hope to reach the ultimate goal of finding a cure for
diabetes.
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